1. Volume 71, Issue 6, Pages 952-960 (June 2017)
Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience 
Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, Andrzej Niemierko, Michael Drumm, Niall M. Heney, Marc D. Michaelson, Richard J. Lee, Philip J. Saylor, Matthew F. Wszolek, Adam S. Feldman, Douglas M. Dahl, Anthony L. Zietman, Jason A. Efstathiou 
European Urology 
Volume 71, Issue 6, Pages (June 2017)
DOI: /j.eururo
Copyright © 2016 European Association of Urology Terms and Conditions

2. Fig. 1
(A and B) Kaplan-Meier plots for rates of disease-specific survival and overall survival, respectively, for all patients; (C and D) stratified by clinical T2 versus T3/4a; (E and F) stratified by induction response status; and (G and H) stratified by extent of transurethral resection of bladder tumor (TURBT).
CR=complete response.
European Urology  , DOI: ( /j.eururo )
Copyright © 2016 European Association of Urology Terms and Conditions

3. Fig. 2
(A) Improvements in overall survival, (B) disease-specific survival, and (C) bladder-intact disease-specific survival, with (D) a reduction in the crude rate of salvage cystectomy over three treatment eras.
European Urology  , DOI: ( /j.eururo )
Copyright © 2016 European Association of Urology Terms and Conditions